MiNK Therapeutics (INKT) Expected to Release Earnings on Wednesday

MiNK Therapeutics (NASDAQ:INKT) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $0.07 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). On average, analysts expect MiNK Therapeutics to post ($2.53) EPS for the current fiscal year and ($2.41) EPS for the next fiscal year.

MiNK Therapeutics Trading Down 0.5%

Shares of INKT opened at $10.30 on Tuesday. MiNK Therapeutics has a 1-year low of $8.48 and a 1-year high of $16.93. The firm has a fifty day simple moving average of $11.21 and a two-hundred day simple moving average of $11.25.

Wall Street Analyst Weigh In

INKT has been the topic of several research reports. Zacks Research cut MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. HC Wainwright initiated coverage on shares of MiNK Therapeutics in a research report on Wednesday, November 4th. They set a “buy” rating and a $38.00 price target for the company. B. Riley Financial reiterated a “buy” rating and issued a $50.00 price objective (up from $43.00) on shares of MiNK Therapeutics in a research note on Wednesday, October 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, MiNK Therapeutics presently has an average rating of “Hold” and an average price target of $44.00.

Insiders Place Their Bets

In other MiNK Therapeutics news, CEO Jennifer Buell sold 6,938 shares of the business’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $10.56, for a total transaction of $73,265.28. Following the completion of the sale, the chief executive officer owned 74,195 shares of the company’s stock, valued at approximately $783,499.20. The trade was a 8.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 20.40% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.